Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 3Other hematologic neoplasm 2Classical hematology 2Plasma cell 1Other neoplasm 1

Conditions

Multiple Myeloma 149Lymphoma 20Recurrence 17Neoplasms 12Hematologic Neoplasms 11Neoplasms, Plasma Cell 9Lymphoma, Non-Hodgkin 9Immunoglobulin Light-chain Amyloidosis 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myelodysplastic Syndromes 5Lymphoma, Mantle-Cell 5Leukemia, Myeloid, Acute 5Hodgkin Disease 5Prostatic Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia 4Breast Neoplasms 4Smoldering Multiple Myeloma 3Ovarian Neoplasms 3Melanoma 3Lymphoma, B-Cell, Marginal Zone 3Lung Neoplasms 3Leukemia, Plasma Cell 3Cytokine Release Syndrome 3Waldenstrom Macroglobulinemia 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Primary Myelofibrosis 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2

Interventions

idecabtagene vicleucel 1fludarabine 1Leukapheresis 1Lenalidomide 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × Plasma cell × 30 days × Clear all
NCT05032820 2026-05-19

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

Medical College of Wisconsin

Phase 2 Completed
40 enrolled 32 charts
Plasma cell

Hematologic Diseases, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡